CD274 and neoplasm: Notably, one case achieved partial remission (PR) following combination therapy with crizotinib and nivolumab due to high PD-L1 expression in tumor tissues but later presented with recurrent pneumonitis resulting from both agents prompting a switch to alectinib  (29).